0001437749-24-003578.txt : 20240313 0001437749-24-003578.hdr.sgml : 20240313 20240209111820 ACCESSION NUMBER: 0001437749-24-003578 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REVIVA PHARMACEUTICALS HOLDINGS, INC. CENTRAL INDEX KEY: 0001742927 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 10080 N WOLFE ROAD STREET 2: SUITE SW3-200 CITY: CUPERTINO STATE: CA ZIP: 95014 BUSINESS PHONE: 4085018881 MAIL ADDRESS: STREET 1: 10080 N WOLFE ROAD STREET 2: SUITE SW3-200 CITY: CUPERTINO STATE: CA ZIP: 95014 FORMER COMPANY: FORMER CONFORMED NAME: Tenzing Acquisition Corp. DATE OF NAME CHANGE: 20180606 CORRESP 1 filename1.htm rvph20240209_corresp.htm

 

 

 

reviva01.jpg

Reviva Pharmaceuticals Holdings, Inc.

 

 

February 9, 2024

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Cindy Polynice

 

 

Re:

Reviva Pharmaceuticals Holdings, Inc.
 

Registration Statement on Form S-3
 

Filed on February 2, 2024
 

File No. 333-276848

 

 

Acceleration Request
 

Requested Date: February 13, 2024
 

Requested Time: 9:00 a.m., Eastern Time

 

Dear Ladies and Gentlemen:

 

In connection with the above-captioned Registration Statement (the "Registration Statement"), and pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Act"), Reviva Pharmaceuticals Holdings, Inc. (the "Company") hereby requests that the above-mentioned Registration Statement be declared effective by the Securities and Exchange Commission (the "Commission") at 9:00 a.m., Eastern Time, on February 13, 2024, or as soon thereafter as practicable.

 

Please call Steven Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.

 

 

Very truly yours, 

 
     
  REVIVA PHARMACEUTICALS HOLDINGS, INC.  

 

 

 

 

 

By:

/s/ Narayan Prabhu 

 

 

 

Name:  Narayan Prabhu 

 

 

 

Title:  Chief Financial Officer 

 

 

 
 GRAPHIC 2 reviva01.jpg begin 644 reviva01.jpg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end